title: Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma.
authors.affiliation: Institut Bergonié, Bordeaux, France y.godbert@bordeaux.unicancer.fr.
authors.forename: Yann
authors.initials: Y
authors.lastname: Godbert
authors.affiliation: Institut Bergonié, Bordeaux, France.
authors.forename: Bénédicte
authors.initials: B
authors.lastname: Henriques de Figueiredo
authors.affiliation: Institut Bergonié, Bordeaux, France.
authors.forename: Françoise
authors.initials: F
authors.lastname: Bonichon
authors.affiliation: Institut Bergonié; and Institut National de la Santé et de la Recherche Médicale U916, Bordeaux, France.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Chibon
authors.affiliation: Institut Bergonié, Bordeaux, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Hostein
authors.affiliation: Institut Bergonié, Bordeaux, France.
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Pérot
authors.affiliation: Laboratoire d'Anatomie et de Cytologie Pathologiques, Bordeaux, France.
authors.forename: Camille
authors.initials: C
authors.lastname: Dupin
authors.affiliation: Cabinet d'Histo Cyto Pathologie, Le Bouscat, France.
authors.forename: Agnès
authors.initials: A
authors.lastname: Daubech
authors.affiliation: University Hospital, Pessac, France.
authors.forename: Genevieve
authors.initials: G
authors.lastname: Belleannée
authors.affiliation: University Hospital, Pessac, France.
authors.forename: Audrey
authors.initials: A
authors.lastname: Gros
authors.affiliation: Institut Bergonié, Bordeaux, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Italiano
authors.affiliation: Institut Bergonié, Bordeaux, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Soubeyran
mesh_terms: D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics*; D001706:Biopsy; D017024:Chemotherapy, Adjuvant; D000077547:Crizotinib; D005260:Female; D015321:Gene Rearrangement; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000556:secondary; D009367:Neoplasm Staging; D057285:Precision Medicine; D011237:Predictive Value of Tests; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics*; D012074:Remission Induction; D065646:Thyroid Carcinoma, Anaplastic / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000556:secondary; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D013965:Thyroidectomy; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases